文献速递消化系统肿瘤

伊帕他塞替联合或不联合mFOLFOX6治疗局部晚期或转移性胃或胃食管结合部癌的II期随机研究

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
PubMed 文献 · Eur J Cancer · 2018-12-25

这项随机、双盲、安慰剂对照、多中心II期试验纳入153例不适合根治治疗的局部晚期或转移性胃/胃食管结合部癌患者,1:1随机接受伊帕他塞替或安慰剂联合mFOLFOX6。意向治疗人群的中位无进展生存期(PFS)为伊帕他塞替组6.6个月(90%CI 5.7-7.5)对安慰剂组7.5个月(90%CI 6.2-8.1),风险比1.12(90%CI 0.81-1.55;P=0.56),未观察到显著PFS获益,生物标志物选择亚组亦无显著获益。

要点

  • 伊帕他塞替联合mFOLFOX6对比安慰剂联合mFOLFOX6未改善意向治疗人群的PFS。
  • 在PTEN低表达及PI3K/Akt通路激活肿瘤亚组中,伊帕他塞替联合mFOLFOX6对比安慰剂联合mFOLFOX6未观察到显著PFS获益。
  • 伊帕他塞替组导致治疗退出的不良事件发生率高于安慰剂组(16%对6%),严重不良事件发生率亦较高(54%对43%)。

核心结论

  • 伊帕他塞替联合mFOLFOX6对比安慰剂联合mFOLFOX6在未选择或生物标志物选择的患者中均未改善PFS。
  • 未观察到非预期安全性问题。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心II期试验。
  • 纳入153例不适合根治治疗的局部晚期或转移性胃/胃食管结合部癌患者,1:1随机接受伊帕他塞替或安慰剂联合mFOLFOX6。
  • 共同主要终点为意向治疗人群和PTEN低表达患者的PFS。

主要发现

  • 意向治疗人群中位PFS:伊帕他塞替/mFOLFOX6组6.6个月(90%CI 5.7-7.5)对安慰剂/mFOLFOX6组7.5个月(90%CI 6.2-8.1),风险比1.12(90%CI 0.81-1.55;P=0.56)。
  • 在PTEN低表达和PI3K/Akt通路激活肿瘤的生物标志物选择亚组中,伊帕他塞替/mFOLFOX6对比安慰剂/mFOLFOX6未观察到统计学显著的PFS获益。
  • 其他次要终点未偏向伊帕他塞替/mFOLFOX6治疗组。
  • 至少1项不良事件发生率:伊帕他塞替组100%对安慰剂组98%;≥3级不良事件发生率:伊帕他塞替组79%对安慰剂组74%。
  • 导致治疗退出的不良事件发生率:伊帕他塞替组16%对安慰剂组6%;严重不良事件发生率:伊帕他塞替组54%对安慰剂组43%;死亡例数:伊帕他塞替组39例对安慰剂组29例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Akt activation is common in gastric/gastroesophageal junction cancer (GC/GEJC) and is associated with chemotherapy resistance. Treatment with ipatasertib, a pan-Akt inhibitor, may potentiate the efficacy of chemotherapy in GC/GEJC. PATIENTS AND METHODS: In this randomised, double-blind, placebo-controlled, multicentre, phase II trial, patients with locally advanced or metastatic GC/GEJC not amenable to curative therapy were randomised 1:1 to receive ipatasertib or placebo, plus mFOLFOX6 (modified regimen of leucovorin, bolus and infusional 5-fluorouracil [5-FU], and oxaliplatin). The co-primary end-point was progression-free survival (PFS) in the intent-to-treat (ITT) population and in phosphatase and tensin homolog (PTEN)-low patients. Secondary end-points included PFS in patients with PI3K/Akt pathway-activated tumours; overall survival, investigator-assessed objective response rate and duration of response in the ITT population; and safety assessments. RESULTS: In 153 enrolled patients, the median PFS (ITT) was 6.6 months (90% confidence interval [CI], 5.7-7.5) with ipatasertib/mFOLFOX6 versus 7.5 months (90% CI, 6.2-8.1) with placebo/mFOLFOX6 (hazard ratio, 1.12; 90% CI, 0.81-1.55; P = 0.56). No statistically significant PFS benefit was observed in biomarker-selected patient subgroups (PTEN-low and PI3K/Akt pathway-activated tumours) with ipatasertib/mFOLFOX6 versus placebo/mFOLFOX6. Other secondary end-points did not favour the ipatasertib/mFOLFOX6 treatment arm. The percentages of patients with ≥1 adverse event (AE, 100% versus 98%) and grade ≥3 AEs (79% versus 74%) were similar between arms. Higher rates of AEs leading to treatment withdrawal (16% versus 6%) and serious AEs were reported in the ipatasertib arm (54% versus 43%). Thirty-nine and 29 deaths occurred in the ipatasertib and placebo arms, respectively. CONCLUSIONS: Ipatasertib/mFOLFOX6 compared with placebo/mFOLFOX6 did not improve PFS in unselected or biomarker-selected patients. No unexpected safety concerns were observed. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01896531).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bang YJ, Kang YK, Ng M, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2018. PMID: 30592991. doi:10.1016/j.ejca.2018.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。